Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture

Blood

Volumn 87, Issue 6, 1996, Pages 2476-2485

  Cervantes, Francisco ^b   Pierson, Bryce A ^b   McGlave, Philip B ^b   Verfaillie, Catherine M ^b   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; HYDROCORTISONE; INTEGRIN; INTERLEUKIN 2; METHYLCELLULOSE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW CULTURE; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0029984379     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2476.bloodjournal8762476     Document Type: Article

References (45)

1. Verfaillie C, Miller W, Kay N, McGlave PB: Adherent lymphokine activated killer (ALAK) cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood 74:793, 1989
2. Verfaillie C, Miller W, Kay N, McGlave PB: Diminished A-LAK cytotoxicity and proliferation accompanies disease progression in chronic myelogenous leukemia. Blood 76:401, 1990
3. Mackinnon S, Bungey J, Case A, Paulsen W, Hows JM, Goldman JM: Origin and function and adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation. Br J Haematol 77:60, 1991
4. Silla L, Pincus SM, Locker JD, Oliveri DO, Glover J, Elder E, Donnenberg AD, Whiteside TL. Characterization of BCR/ABL natural killer (NK) cells from patients with chronic myelogenous leukemia. Blood 82:1512a, 1993 (abstr)
5. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA: Antileukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250, 1990
6. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992
7. Bhatia R, McGlave PB, Verfaillie CM: Treatment of marrow stroma with interferin-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. J Clin Invest 96:931, 1995
8. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF. Tricot G, Hoffman R: Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 81:801, 1993
9. lo population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization. Blood 86:737, 1995
10. Miller JS, Verfaillie C, McGlave B: Expansion and activation of human natural killer cells for autologous therapy. J Hematotherapy 3:71, 1994
11. - primitive progenitors in human long-term bone marrow culture. Blood 80:2182, 1992
12. Matera L, Cardoso E, Veglia F, Cesano A, Bellone G, Vuolo A, Molinatti GM: Effect of cortisol on the native and in vitro induced non-MHC restricted cytotoxicity of large granular lymphocytes. J Clin Lab Immunol 27:77, 1988
13. Verfaillie CM: Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood 79:2821, 1992
14. - cells reselected from macrophage inflammatory protein 1α + interleukin-3-supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture-initiating cells Blood 84:1442, 1994
15. Burrhoughs J, Gupta P, Blazar B, Verfaillie CM: Diffusible factors from the murine cell line M2-10B4 support human in vitro hematopoiesis. Exp Hematol 22:1095, 1994
16. Miller JS, Oelkers S, Verfaillie C, McGlave P: The role of monocytes in the expansion of human activated natural killer cells. Blood 80:2221, 1992
17. Pierson BA, McGlave PB, Hu WS, Miller JS: Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. J Hematotherapy 4:149, 1995
18. Pierson BA, Gupta K, Hu WS, Miller JS: Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-β1 and independent accessory cell-derived contact and soluble factors. Blood 87:180, 1996
19. Miller JS, Klingsporn SO, Lund J, Perry EH, Verfaillie CM, McGlave PB: Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 14:555, 1994
20. Klingemann HG, Deal H, Reid D, Eaves CJ: Design and validation of a clinically applicable culture procedure for generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21:1263, 1993
21. Herrmann F, Schmidt RE, Ritz J, Griffin JD: In vitro regulation of human hematopoiesis by natural killer cells: Analysis at a clonal level. Blood 69:246, 1987
22. Degliantoni G, Perussia B, Mongoni L, Trinchieri G: Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity. J Exp Med 161:1152, 1985
23. Skettino S, Phillips J, Lanier L, Nagler A, Greenberg P: Selective generation of erythroid burst-promoting activity by recombinant interleukin 2-stimulated human T lymphocytes and natural killer cells. Blood 71:907, 1988
24. Niemeyer CM, Sieff CA, Smith BR, Ault KA, Nathan DG: Hematopoiesis in vitro coexists with natural killer lymphocytes. Blood 74:2376, 1989
25. Nagler A, Greenburg PL, Lanier LL, Phillips JH: The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors. J Exp Med 168:47, 1988
26. Hansson M, Beran M, Andersson B, Kiessling R: Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol 129:126, 1982
27. Matera L, Santoli D, Garbarino G, Pegoraro L, Bellone G, Pagliardi G: Modulation of in vitro myelopoiesis by LGL: Different effects on early and late progenitor cells. J Immunol 136:1260, 1986
28. Mangan KF, Hartnett ME, Matis SA, Winkelstein A, Abo T: Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood 63:260, 1984
29. van der Brink MRM, Voogt PJ, Marijt WAF, van Luxemberg-Heys SAP, van Rood JJ, Brand A: Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 74:354, 1989
30. Fujimori Y, Hara H, Hagai K: Effect of lymphokine-activated killer cell fraction on the development of human hematopoietic progenitor cells. Cancer Res 48:534, 1987
31. Miller JS, Verfaillie C, McGlave P: Adherent lymphokine-activated killer (A-LAK) cells suppress autologous human normal bone marrow progenitors. Blood 77:2389, 1991
32. Miller JS: NK-cell target recognition and killing is activation-dependent and target specific, in Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (eds): Leukocyte Typing V: White Cell Differentiation Antigens. Proceedings of the Fifth International Workshop and Conference. Boston. MA, Oxford, 1995, p 1431
33. Hogg N: The leukocyte integrins. Immunol Today 4:111, 1989
34. Staunton DE, Dustin ML, Springer TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339:61, 1989
35. Miller JS, McGlave PB: Therapy of chronic myelogenous leukemia with marrow transplantation. Curr Opin Oncol 5:262, 1993
36. Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, Lercari G, Sessarego M, Defferrari R, Guerrasio A, Saglio G, Canepa L, Gaetani GF, Ochini D: Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 5:517, 1991
37. McGlave P, Arthur D, Miller WJ, Lasky L. Kersey J: Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 6:115, 1990
38. Turhan AG, Humphries KRK, Eaves CJ, Barnett MJ, Phillips GL, Kalousek DK, Klingemann HG, Lansdorp PL, Reece DE, Shepherd JD, Eaves AC: Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood 76:2402, 1990
39. Reiffers J, Trouette R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou-Nabera C, Lacombe F, Feuillatre-Fabre F, Vezon G, Bernard PH, Brousted A: Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol 77:339, 1991
40. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplant therapy for chronic myelogenous leukemia prolongs survival: Results from eight transplant groups. Lancet 343:1486, 1994
41. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994
42. Sznol M, Parkinson DR: Interleukin-2 in therapy of hematoiogic malignancies. Blood 83:2020, 1994
43. Bilgrami S, Silva M, Cardoso A, Miller KB, Ascensao JL: Immunotherapy with autologous bone marrow transplantation: Rationale and results. Exp Hematol 22:1039, 1994
44. Agah R, Malloy B, Kerner M, Gingis E, Bean P, Twomey P, Mazumder A: Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice. Cancer Res 49:5959, 1989
45. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187, 1990